B74 Malignant neoplasm blood other (ICD-10:C96.9)

Introduction

Malignant neoplasm of blood other than leukemia or lymphoma encompasses a rare group of cancers affecting blood cells, bone marrow, or lymphatic system. This category includes histiocytic and dendritic cell neoplasms, characterized by uncontrolled growth of abnormal blood cells^[1][2]. These rare malignancies represent less than 1% of all hematopoietic cancers and present significant diagnostic and therapeutic challenges^[3]. This guide provides an evidence-based overview of symptoms, causes, diagnostic approaches, and treatment interventions for these conditions.

Codes

• ICPC-2 Code: B74 Malignant neoplasm blood other^[4]
• ICD-10 Code: C96.9 Malignant neoplasm of lymphoid, haematopoietic and related tissue, unspecified^[1]

Symptoms

Clinical presentations vary significantly depending on the specific neoplasm type and extent of disease^[5][6]:

Systemic symptoms:

• Fatigue and weakness: Due to abnormal blood cell production affecting oxygen delivery and immune function^[5]
• Unexplained weight loss: Often exceeding 10% of body weight over 6 months^[6]
• Night sweats: Excessive perspiration during sleep^[5]
• Fever: Persistent or recurrent elevated temperature^[6]

Hematologic manifestations:

• Frequent infections: Increased susceptibility due to compromised immune cell function^[5]
• Easy bruising or bleeding: Results from decreased platelet count or function^[5]
• Shortness of breath: May indicate anemia or lung involvement^[6]

Physical findings:

• Enlarged lymph nodes: Painless swelling in neck, armpits, or groin, most commonly presenting symptom^[7]
• Bone pain: Particularly in cases with bone marrow involvement^[5]
• Abdominal pain: May indicate liver or spleen enlargement^[8]

Causes

The exact etiology remains largely unknown, with most cases appearing sporadically^[3][9]. Several risk factors have been identified:

• Genetic factors: Most cases involve acquired genetic mutations rather than inherited conditions. Specific mutations including MAPK pathway activation have been identified in histiocytic sarcomas^[9].
• Environmental exposures: Previous radiation exposure, certain chemical exposures (including benzene), and viral infections may increase risk^[3].
• Secondary neoplasms: Approximately 10-20% of histiocytic sarcomas occur secondary to other hematologic malignancies, particularly B-cell lymphomas^[9].
• Associated conditions: Some cases are associated with Castleman’s disease or Epstein-Barr virus infection, particularly in liver and spleen involvement^[7].

Diagnostic Steps

Medical History

• Comprehensive symptom assessment including duration, severity, and progression^[5]
• Detailed evaluation of risk factors including radiation or chemical exposures^[5]
• Assessment of family history of hematologic malignancies or genetic syndromes^[5]
• Review of concurrent medical conditions and medications^[5]

Physical Examination

• Thorough examination for lymphadenopathy, hepatosplenomegaly, and skin lesions^[5]
• Assessment of performance status and signs of systemic illness^[6]
• Evaluation for bone tenderness or masses^[5]

Laboratory Tests

• Complete blood count (CBC) with differential: Evaluates all blood cell lines and may reveal cytopenias or abnormal cells^[5].
• Comprehensive metabolic panel: Assesses liver and kidney function, electrolytes, and markers of tumor lysis syndrome^[5].
• Bone marrow biopsy: Essential for definitive diagnosis, evaluating morphology, immunophenotype, and genetic abnormalities^[10].
• Flow cytometry: Analyzes cell surface markers to identify specific cell lineages and differentiate subtypes^[10].
• Immunohistochemistry: Critical for diagnosis using specific markers including CD68, CD1a, Langerin (CD207), S-100, and others depending on suspected subtype^[3][9].

Diagnostic Imaging

• CT scan: Provides detailed assessment of lymph nodes, organ involvement, and disease extent^[5].
• PET/CT scan: Valuable for detecting metabolically active disease and assessing treatment response^[11].
• MRI: Particularly useful for evaluating central nervous system or bone involvement^[5].
• Chest X-ray: Initial screening for pulmonary involvement^[5].

Other Tests

• Molecular testing: Identifies specific genetic mutations that may guide targeted therapy selection^[9].
• Cytogenetic analysis: Evaluates chromosomal abnormalities important for prognosis and treatment planning^[10].
• Lumbar puncture: Performed when central nervous system involvement is suspected^[5].

Follow-up and Patient Education

• Establish regular monitoring schedule based on disease type and treatment response^[5]
• Provide comprehensive education about disease prognosis and treatment options^[5]
• Connect patients with support resources and specialized centers^[5]

Possible Interventions

Traditional Interventions

Medications:

Chemotherapy (Cyclophosphamide, Vincristine, Prednisone):

• Cost: $15,000-$40,000 per treatment course^[12]
• Contraindications: Active severe infections, severe organ dysfunction
• Side effects: Nausea, hair loss, fatigue, myelosuppression
• Severe side effects: Severe infections, secondary malignancies, organ toxicity
• Warning: Requires regular monitoring with complete blood counts and organ function tests^[13]

Targeted therapy (Imatinib, Sorafenib, Bevacizumab):

• Cost: $8,000-$25,000 per year depending on specific agent^[12]
• Contraindications: Severe hepatic impairment, active bleeding disorders
• Side effects: Diarrhea, rash, fatigue, edema
• Severe side effects: Cardiac toxicity, bleeding complications, liver dysfunction
• Warning: Novel targeted approaches show promise with expression of PDGFR, VEGFR, and EGFR markers^[14]

Immunotherapy (PD-1/PD-L1 inhibitors):

• Cost: $12,000-$30,000 per month^[12]
• Contraindications: Autoimmune diseases, severe immune-related adverse events
• Side effects: Fatigue, rash, immune-related organ inflammation
• Severe side effects: Pneumonitis, hepatitis, colitis, endocrinopathies
• Warning: Emerging evidence shows efficacy in histiocytic sarcomas expressing PD-L1^[15]

Treatment modalities:

Radiation therapy:

• Cost: $10,000-$30,000 for complete course^[12]
• Contraindications: Previous radiation to same area, pregnancy
• Side effects: Local skin reactions, fatigue, organ-specific effects
• Severe side effects: Secondary cancers, organ dysfunction
• Warning: Effective for localized disease with typical doses of 40-50 Gray^[16]

Stem cell transplantation:

• Cost: $200,000-$500,000 depending on type and complications^[12]
• Contraindications: Advanced age, severe comorbidities, active infection
• Side effects: Graft-versus-host disease, prolonged immunosuppression
• Severe side effects: Treatment-related mortality, organ failure
• Warning: Considered for eligible patients with aggressive disease^[13]

Surgical Procedures

• Complete surgical resection: Median survival not reached for patients undergoing surgical resection in advanced follicular dendritic cell sarcoma, with 80% alive at long-term follow-up^[17]. Cost: $20,000-$60,000 depending on complexity^[12].
• Debulking surgery: May provide symptom relief and facilitate other treatments^[16]. Cost: $15,000-$45,000^[12].

Alternative Interventions

• Acupuncture: May help manage treatment-related symptoms including nausea, fatigue, and pain. Studies demonstrate effectiveness in reducing chemotherapy-induced side effects^[18]. Cost: $60-$120 per session.
• Mind-body techniques: Meditation, yoga, and tai chi can reduce stress and improve quality of life during treatment^[19]. Cost: $50-$150 per session.
• Nutritional counseling: Professional guidance on maintaining optimal nutrition during treatment^[19]. Cost: $100-$200 per consultation.
• Massage therapy: Can reduce treatment-related stress and improve circulation^[18]. Cost: $60-$120 per session.

Lifestyle Interventions

• Nutrition optimization: A diet rich in antioxidants, omega-3 fatty acids, and dietary fiber may reduce inflammation and support immune function during treatment^[20][21].
• Appropriate exercise: Regular physical activity as tolerated can improve energy levels, reduce fatigue, and maintain muscle mass during treatment^[19].
• Stress management: Evidence-based techniques including mindfulness, meditation, and cognitive-behavioral strategies can improve psychological well-being and treatment tolerance^[19].
• Sleep hygiene: Maintaining consistent sleep patterns supports immune function and recovery^[19].
• Social support: Engagement with support groups, mental health professionals, and patient advocacy organizations improves outcomes and quality of life^[19].

Note: Treatment costs vary significantly by geographic location, insurance coverage, and specific protocols. These rare diseases require management at specialized centers with expertise in hematopoietic malignancies. Prognosis varies widely, with follicular dendritic cell sarcoma showing 5-year survival rates of approximately 60%, while other subtypes may have more aggressive courses^[22][16].

Mirari Cold Plasma Alternative Intervention

Understanding Mirari Cold Plasma

• Safe and Non-Invasive Treatment: Mirari Cold Plasma is a safe and non-invasive treatment option for various skin conditions. It does not require incisions, minimizing the risk of scarring, bleeding, or tissue damage.
• Efficient Extraction of Foreign Bodies: Mirari Cold Plasma facilitates the removal of foreign bodies from the skin by degrading and dissociating organic matter, allowing easier access and extraction.
• Pain Reduction and Comfort: Mirari Cold Plasma has a local analgesic effect, providing pain relief during the treatment, making it more comfortable for the patient.
• Reduced Risk of Infection: Mirari Cold Plasma has antimicrobial properties, effectively killing bacteria and reducing the risk of infection.
• Accelerated Healing and Minimal Scarring: Mirari Cold Plasma stimulates wound healing and tissue regeneration, reducing healing time and minimizing the formation of scars.

Mirari Cold Plasma Prescription

Video instructions for using Mirari Cold Plasma Device – B74 Malignant neoplasm blood other (ICD-10:C96.9)

Mild	Moderate	Severe
Mode setting: 1 (Infection) Location: 1 (Sacrum) Morning: 15 minutes, Evening: 15 minutes	Mode setting: 1 (Infection) Location: 1 (Sacrum) Morning: 30 minutes, Lunch: 30 minutes, Evening: 30 minutes	Mode setting: 1 (Infection) Location: 1 (Sacrum) Morning: 30 minutes, Lunch: 30 minutes, Evening: 30 minutes
Mode setting: 2 (Wound Healing) Location: 1 (Sacrum) Morning: 15 minutes, Evening: 15 minutes	Mode setting: 2 (Wound Healing) Location: 1 (Sacrum) Morning: 30 minutes, Lunch: 30 minutes, Evening: 30 minutes	Mode setting: 2 (Wound Healing) Location: 1 (Sacrum) Morning: 30 minutes, Lunch: 30 minutes, Evening: 30 minutes
Mode setting: 3 (Antiviral Therapy) Location: 1 (Sacrum) Morning: 15 minutes, Evening: 15 minutes	Mode setting: 3 (Antiviral Therapy) Location: 1 (Sacrum) Morning: 30 minutes, Lunch: 30 minutes, Evening: 30 minutes	Mode setting: 3 (Antiviral Therapy) Location: 1 (Sacrum) Morning: 30 minutes, Lunch: 30 minutes, Evening: 30 minutes
Mode setting: 7 (Immunotherapy) Location: 1 (Sacrum) Morning: 15 minutes, Evening: 15 minutes	Mode setting: 7 (Immunotherapy) Location: 1 (Sacrum) Morning: 30 minutes, Lunch: 30 minutes, Evening: 30 minutes	Mode setting: 7 (Immunotherapy) Location: 1 (Sacrum) Morning: 30 minutes, Lunch: 30 minutes, Evening: 30 minutes
Total Morning: 60 minutes approx. $10 USD, Evening: 60 minutes approx. $10 USD	Total Morning: 120 minutes approx. $20 USD, Lunch: 120 minutes approx. $20 USD, Evening: 120 minutes approx. $20 USD,	Total Morning: 120 minutes approx. $20 USD, Lunch: 120 minutes approx. $20 USD, Evening: 120 minutes approx. $20 USD,
Usual treatment for 7-60 days approx. $140 USD – $1200 USD	Usual treatment for 6-8 weeks approx. $2,520 USD – $3,360 USD	Usual treatment for 3-6 months approx. $5,400 USD – $10,800 USD

Localized (0) Sacrum (1) Prostate & Uterus (2) Kidney, Liver & Spleen (3) Heart, Bile & Pancreas (4) Lungs (5) Throat, Lymphatic & Thyroid (6) Neuro system & ENT (7)

Use the Mirari Cold Plasma device to treat Malignant neoplasm blood other effectively.

WARNING: MIRARI COLD PLASMA IS DESIGNED FOR THE HUMAN BODY WITHOUT ANY ARTIFICIAL OR THIRD PARTY PRODUCTS. USE OF OTHER PRODUCTS IN COMBINATION WITH MIRARI COLD PLASMA MAY CAUSE UNPREDICTABLE EFFECTS, HARM OR INJURY. PLEASE CONSULT A MEDICAL PROFESSIONAL BEFORE COMBINING ANY OTHER PRODUCTS WITH USE OF MIRARI.

Step 1: Cleanse the Skin

• Start by cleaning the affected area of the skin with a gentle cleanser or mild soap and water. Gently pat the area dry with a clean towel.

Step 2: Prepare the Mirari Cold Plasma device

• Ensure that the Mirari Cold Plasma device is fully charged or has fresh batteries as per the manufacturer’s instructions. Make sure the device is clean and in good working condition.
• Switch on the Mirari device using the power button or by following the specific instructions provided with the device.
• Some Mirari devices may have adjustable settings for intensity or treatment duration. Follow the manufacturer’s instructions to select the appropriate settings based on your needs and the recommended guidelines.

Step 3: Apply the Device

• Place the Mirari device in direct contact with the affected area of the skin. Gently glide or hold the device over the skin surface, ensuring even coverage of the area experiencing.
• Slowly move the Mirari device in a circular motion or follow a specific pattern as indicated in the user manual. This helps ensure thorough treatment coverage.

Step 4: Monitor and Assess:

• Keep track of your progress and evaluate the effectiveness of the Mirari device in managing your Malignant neoplasm blood other. If you have any concerns or notice any adverse reactions, consult with your health care professional.

Note

This guide is for informational purposes only and should not replace the advice of a medical professional. Always consult with your healthcare provider or a qualified medical professional for personal advice, diagnosis, or treatment. Do not solely rely on the information presented here for decisions about your health. Use of this information is at your own risk. The authors of this guide, nor any associated entities or platforms, are not responsible for any potential adverse effects or outcomes based on the content.

Mirari Cold Plasma System Disclaimer

• Purpose: The Mirari Cold Plasma System is a Class 2 medical device designed for use by trained healthcare professionals. It has received clearance from the U.S. FDA and is registered for use in Thailand and Vietnam. It is not intended for use outside of these locations.
• Informational Use: The content and information provided with the device are for educational and informational purposes only. They are not a substitute for professional medical advice or care.
• Variable Outcomes: While the device is approved for specific uses, individual outcomes can differ. We do not assert or guarantee specific medical outcomes.
• Consultation: Prior to utilizing the device or making decisions based on its content, it is essential to consult with a Certified Mirari Tele-Therapist and your medical healthcare provider regarding specific protocols.
• Liability: By using this device, users are acknowledging and accepting all potential risks. Neither the manufacturer nor the distributor will be held accountable for any adverse reactions, injuries, or damages stemming from its use.
• Geographical Availability: This device has received approval for designated purposes by the Thai and Vietnam FDA. As of now, outside of Thailand and Vietnam, the Mirari Cold Plasma System is not available for purchase or use.

References

1. Gesund Bund. (2025). ICD-10 code: C96.9 Malignant neoplasm of lymphoid, haematopoietic and related tissue, unspecified. https://gesund.bund.de/en/icd-code-search/c96-9
2. World Health Organization. (2010). ICD-10 Version:2010 – C96 Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue. https://icd.who.int/browse10/2010/en
3. Shimono J, et al. (2017). Prognostic factors for histiocytic and dendritic cell neoplasms. Oncotarget. https://www.oncotarget.com/article/21920/text/
4. Cyprus Ministry of Health. (2020). ICPC-2 – English Classification. https://www.gesy.org.cy/el-gr/annualreport/icpc-2-english1-10.pdf
5. Philip DSJ, et al. (2022). Histiocytic Sarcoma: Clinical Features and Outcomes in the Modern Era. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC9271260/
6. Cancer Research UK. (2025). Follicular dendritic cell sarcoma symptoms and diagnosis. https://www.cancerresearchuk.org/about-cancer/soft-tissue-sarcoma/types/follicular-dendritic-cell-fdc-sarcoma
7. Cancer Research UK. (2025). Follicular dendritic cell sarcoma | Types of soft tissue sarcoma. https://www.cancerresearchuk.org/about-cancer/soft-tissue-sarcoma/types/follicular-dendritic-cell-fdc-sarcoma
8. Cincinnati Children’s Hospital. (2020). Langerhans Cell Histiocytosis | Symptoms, Diagnosis & Treatment. https://www.cincinnatichildrens.org/health/l/langerhans-cell-histiocytosis-lch
9. PathologyOutlines.com. (2024). Interdigitating dendritic cell / reticulum cell sarcoma. https://www.pathologyoutlines.com/topic/lymphnodesinterdigitatingreticulum.html
10. Yamada R, et al. (2024). Histiocytic neoplasms: a brief review and differential diagnosis. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC11528248/
11. Al-Ibraheem A, et al. (2022). PET-CT in Clinical Adult Oncology: I. Hematologic Malignancies. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC9738711/
12. Bookimed. (2024). Treatment costs for rare hematologic malignancies. https://us-uk.bookimed.com/article/how-much-leukemia-treatment-costs/
13. Schlick K, et al. (2012). Histiocytic sarcoma – targeted therapy: novel therapeutic options? A series of 4 cases. PubMed. https://pubmed.ncbi.nlm.nih.gov/22846978/
14. Schlick K, et al. (2012). Histiocytic sarcoma – targeted therapy: novel therapeutic options? Onkologie. https://pubmed.ncbi.nlm.nih.gov/22846978/
15. Imataki O, et al. (2022). Application of PD‑L1 blockade in refractory histiocytic sarcoma. Spandidos Publications. https://www.spandidos-publications.com/10.3892/mco.2022.2569
16. Monnier J, et al. (2016). Mast cell sarcoma: new cases and literature review. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC5323235/
17. American Society of Hematology. (2024). Follicular Dendritic Cell Sarcoma: Insights into Characteristics and Outcomes. ASH Publications. https://ashpublications.org/blood/article/144/Supplement%201/6316/528132/Follicular-Dendritic-Cell-Sarcoma-Insights-into
18. Xu J, et al. (2022). Acupuncture for Female Infertility: Discussion on Action Mechanisms and Clinical Applications. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC9273356/
19. Arabmoorchegani M, et al. (2025). Integrative Cancer Care: Leveraging Nutrition and Positive Psychology for Optimal Outcomes. WAOCP Journal. https://waocp.com/journal/index.php/apjcn/article/view/1796
20. Xiao YL, et al. (2024). Effects of dietary intervention on human diseases: molecular mechanisms and therapeutic potential. Nature. https://www.nature.com/articles/s41392-024-01771-x
21. Montégut L, et al. (2022). Science-Driven Nutritional Interventions for the Prevention and Treatment of Cancer. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC10749912/
22. Chen S, et al. (2023). Survival analysis in patients with follicular dendritic cell sarcoma: A population-based study. PubMed. https://pubmed.ncbi.nlm.nih.gov/37732620/